Katy Moore - Search Results

Year	Number of Results
2002	3
2004	1
2017	1
2018	2
2019	2
2020	1
2021	2
2022	2

1

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG). Thwaites GE, et al. Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14. Lancet. 2018. PMID: 29249276 Free PMC article. Clinical Trial.

2

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.

Magee M, Slater J, Mannino F, Ackerman P, Llamoso C, Moore K. Magee M, et al. Among authors: moore k. J Clin Pharmacol. 2021 Jul;61(7):939-953. doi: 10.1002/jcph.1810. Epub 2021 Jan 18. J Clin Pharmacol. 2021. PMID: 33368327

3

Clinical pharmacokinetics of intranasal sumatriptan.

Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Fuseau E, et al. Among authors: moore kh. Clin Pharmacokinet. 2002;41(11):801-11. doi: 10.2165/00003088-200241110-00002. Clin Pharmacokinet. 2002. PMID: 12190330 Review.

4

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes D. Quercia R, et al. Among authors: moore k. J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):125-135. doi: 10.1097/QAI.0000000000001660. J Acquir Immune Defic Syndr. 2018. PMID: 29474268 Free PMC article. Review.

5

Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.

Wire MB, Magee M, Ackerman P, Llamoso C, Moore K. Wire MB, et al. Among authors: moore k. HIV Res Clin Pract. 2021 Dec 9;23(1):1-8. Epub 2022 Mar 14. HIV Res Clin Pract. 2021. PMID: 35285786 Clinical Trial.

6

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.

Lagishetty C, Moore K, Ackerman P, Llamoso C, Magee M. Lagishetty C, et al. Among authors: moore k. Clin Transl Sci. 2020 Jul;13(4):769-776. doi: 10.1111/cts.12763. Epub 2020 Mar 19. Clin Transl Sci. 2020. PMID: 32027457 Free PMC article. Clinical Trial.

7

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.

Moore K, Magee M, Sevinsky H, Chang M, Lubin S, Myers E, Ackerman P, Llamoso C. Moore K, et al. Br J Clin Pharmacol. 2019 Aug;85(8):1771-1780. doi: 10.1111/bcp.13964. Epub 2019 Jun 5. Br J Clin Pharmacol. 2019. PMID: 30980734 Free PMC article. Clinical Trial.

8

Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.

White E, Dunn DT, Desai M, Gafos M, Kirwan P, Sullivan AK, Clarke A, McCormack S; PROUD study group. White E, et al. Sex Transm Infect. 2019 Sep;95(6):449-454. doi: 10.1136/sextrans-2018-053808. Epub 2019 Mar 27. Sex Transm Infect. 2019. PMID: 30918121 Free PMC article. Clinical Trial.

9

Population Pharmacokinetics of Cabotegravir Following Administration of Oral Tablet and Long-Acting Intramuscular Injection in Adult HIV-1-Infected and Uninfected Subjects.

Han K, Baker M, Lovern M, Paul P, Xiong Y, Patel P, Moore KP, Seal CS, Cutrell AG, D'Amico RD, Benn PD, Landovitz RJ, Marzinke MA, Spreen WR, Ford SL. Han K, et al. Among authors: moore kp. Br J Clin Pharmacol. 2022 Jun 13. doi: 10.1111/bcp.15439. Online ahead of print. Br J Clin Pharmacol. 2022. PMID: 35695476

10

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.

Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Moore K, et al. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22. Antimicrob Agents Chemother. 2022. PMID: 35315687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results